In addition to having a roster of healthcare giants including Takeda, Astellas Pharma and Eisai, Japan is also an Asian hotspot for biotech companies. While historically lacking in foreign investments, Japan’s biotech scene is thriving with global investors showing increasing interest. Founded in 2018 as a spinout from Nagoya University, Craif has become one of Japan’s leading Bio-AI companies, focusing on non-invasive diagnostics. Japan’s academic excellenceJapan’s biotech industry is associated with major pharmaceutical companies. Regenerative medicine remains Japan’s defining strength, with biotech companies advancing iPSC-derived therapies for the heart and liver, alongside diversified regenerative approaches.